Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

PRX-115

Phase 2Biologic

PRX-115 is one of 8 biologic programs targeting Methotrexate. It is currently in Phase 2.

1

Indications

2

Total Trials

1

Active Trials

7

Competitors

Pipeline

Status by Indication[3][1]

Indication

MethotrexateRecruiting

MethotrexatePhase 2

Recruiting

Competition

Competitive Landscape

9 competitors in Methotrexate

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Xeljanz

PPrism Pharmaceuticals

Jaypirca

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Bavencio

Neoral

Rifampicin

Boehringer Ingelheim

PRX-115

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Methotrexate

NCT07280156

Clinical

Trials by Indication[1]

Methotrexate1 trial

A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)

Recruiting·PProtalix·Phase 2·NCT07280156·150 enrolled

Uric Acid1 trial

A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels

Completed·PProtalix·Phase 1·NCT05745727·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PRX-115. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PRX-115 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PRX-115. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Protalix company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: PProtalix

Related News